Marc Coucke

Marc Coucke, who studied Pharmacy at the University of Ghent and holds an MBA in General Management from Vlerick, founded Alychlo in 2015.  As Chairman of Alychlo, Marc has become a major investor in many business in various categories. Before that, Marc Coucke was co-founder of the Belgian pharmaceutical company Omega Pharma. Marc Coucke founded Omega Pharma NV in 1987 and developed the company into a leading pan-European OTC health and personal care business.  He was both chairman and chief executive officer of the company.  In 2002 he was awarded the EY Flemish Entrepreneur of the Year. Following the sale of Omega Pharma to Perrigo in 2015, Marc Coucke invests via his private investment firm Alychlo NV in several listed and non-listed companies.  Alychlo invests directly in companies, makes select fund investments and manages a long-term small- and mid-cap equities portfolio.  Alychlo particularly focuses on direct investments and works closely with management as pro-active, hands-on investors and board members.  While Alychlo is also active in other areas, direct investments are mostly in the healthcare and leisure sectors.   Following companies are part of the portfolio of Alychlo : Animalcare, Ceres Pharma, Cim Capital Restruct, Comate, Crescent, Droia, Ekopak, Energy Vision, Fagron, Greenyard, ICT, La Petite Merveille, La Réserve, Lotus, Maison Rouge, miDiagnostics, Mithra, Mitiska, Otra Solutions, Pairi Daiza, Royal Sporting Club Anderlecht, SmartFin, Smartphoto, SnowWorld, Sophia Genetics, Terbeke, The Italian Sea Group, Triginta, VGP, Versluys Groep, Volta Ventures, Waterland, Xior.